focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBYOT.L Regulatory News (BYOT)

  • There is currently no data for BYOT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Secondary Trading on Asset Match

29 Apr 2024 14:15

RNS Number : 4497M
Byotrol PLC
29 April 2024
 

 

 

Byotrol Plc

("Byotrol" or the "Company")

 

Secondary Trading on Asset Match Following Cancellation

 

Byotrol Plc is pleased to announce that Asset Match (www.assetmatch.com) have been appointed to facilitate secondary trading in the New Ordinary shares following the upcoming cancellation of admission to trading on AIM (the "Cancellation").

As previously announced, following approval by shareholders at the General Meeting held on 22nd April 2024, the Cancellation will take effect from 7.00 a.m. on 30th April 2024.

Following the Cancellation, the New Ordinary shares will be admitted to trading on the off-market dealing facility on 30th April 2024.

Asset Match, a firm Authorised and Regulated by the Financial Conduct Authority (FRN 579310), will operate an electronic off-market dealing facility for the New Ordinary shares. This facility will allow existing shareholders of the Company ("Shareholders") and new investors to trade the New Ordinary shares by matching buyers and sellers through periodic auctions.

Investors are encouraged to register on www.assetmatch.com and add Byotrol Plc to their 'Watchlist' to continue to receive Company updates and auction/price information.

The Asset Match trading facility operates under its own code of practice which governs the behaviour of participants and the running of the periodic auctions. Asset Match operates an open auction system where volumes of bids and offers at different prices are displayed on-screen together with the closing date of the auction. At the end of each auction period, Asset Match passes this information through a non-discretionary algorithm that determines a "market-derived" single clearing price ("Share Price") based on supply and demand and allocates transactions accordingly. Bids and offers may be made, amended and withdrawn at any time before the closing date of each auction.

Shareholders will continue to be able to hold their shares in uncertificated form (i.e. in CREST) and should check with their existing stockbroker whether they are willing or able to trade in unquoted shares. Shareholders wishing to trade shares through Asset Match must do so through a stockbroker. A comprehensive list of stockbrokers who have signed up to access the Asset Match platform is available on request.

Full details will be made available to Shareholders on the Company's website at www.byotrol.com. Investors may contact Asset Match in relation to any queries regarding trading via the secondary market trading facility by emailing dealing@assetmatch.com.

 

Further details of the Cancellation and re-registration were set out in the circular dated 28 March 2024 ("the Circular"). A copy of the Circular is available on the Company's website www.byotrol.com

 

Unless otherwise indicated, defined terms in this announcement shall have the same meaning as described in the Circular.

 

For further information contact:

 

Byotrol Plc

Ashley Head, Non- Executive Chairman

+44 (0)1925 742 000

David Traynor, Interim Chief Executive Officer

Chris Sedwell, Chief Financial Officer

 

Asset Match

+44 (0)20 7248 2788

Ben Weaver

Hannah Woodley

 

 

 

 

 

 

Notes to editors

 

Byotrol plc (BYOT.L), quoted on AIM, is a specialist infection prevention and control company, operating globally in the animal and human healthare, industrial, institutional and consumer sectors, providing low toxicity products with a broad-based and targeted efficacy across all microbial classes; bacteria, viruses (including coronavirus), fungi, moulds, mycobacteria and algae.

 

Byotrol's products can be used stand-alone or as ingredients within existing products, where they can significantly improve their performance, especially in personal hygiene, domestic and industrial disinfection, odour control, food production and food management.

 

Byotrol develops and commercialises technologies that create easier, safer and cleaner lives for everyone.

 

For more information, go to byotrol.com

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSELFDUELSESL
Date   Source Headline
30th Apr 20247:00 amRNSCancellation - Byotrol Plc
29th Apr 20242:15 pmRNSSecondary Trading on Asset Match
23rd Apr 20246:00 pmRNSByotrol
22nd Apr 20244:44 pmRNSCapital Reorganisation Delay
22nd Apr 20241:27 pmRNSResults of General Meeting
15th Apr 202411:48 amRNSHolding(s) in Company
8th Apr 20247:00 amRNSHolding(s) in Company
2nd Apr 20243:27 pmRNSDirector Dealing
28th Mar 20247:00 amRNSProposed Cancellation
22nd Dec 202311:44 amRNSHolding(s) in Company
7th Dec 20237:00 amRNSHalf-year Report
14th Nov 20237:00 amRNSLaunch of PROCESSUS® Instrument Decontamination
14th Nov 20237:00 amRNSTrading Update
9th Nov 20233:43 pmRNSHolding(s) in Company
27th Sep 20237:00 amRNSBoard Changes
13th Sep 20233:33 pmRNSResult of AGM
8th Sep 20234:33 pmRNSDirector Dealing
7th Sep 20237:01 amRNSBoard Appointment
7th Sep 20237:00 amRNSTrading Update
29th Aug 20238:51 amRNSLaunch of CHEMGENE MEDLAB into human healthcare
23rd Aug 20237:00 amRNSInvestor Presentation via Investor Meet Company
31st Jul 20237:00 amRNSFinal Results
6th Jul 20237:00 amRNSPatent Grant for Novel Anti-viral Seaweed Extract
24th May 20233:14 pmRNSUS EPA approves Byotrol24 as long-lasting virucide
24th May 20238:51 amRNSDirector Dealing
28th Apr 20239:57 amRNSDirector Dealing
27th Apr 20237:00 amRNSTrading Update and Board Changes
1st Feb 20239:52 amRNSDirector Dealing
22nd Dec 20223:08 pmRNSDirector Dealing
19th Dec 202210:00 amRNSDirector Dealing
16th Dec 20227:00 amRNSGrant of Share Incentive Awards
12th Dec 20227:00 amRNSInterim results and Investor Presentation
22nd Nov 20227:00 amRNSDirectorate Changes
27th Sep 202211:15 amRNSPDMR Shareholding
22nd Sep 20225:21 pmRNSResult of AGM
8th Sep 20227:00 amRNSDirector Dealing
2nd Sep 202210:02 amRNSInvestor Presentation
30th Aug 20227:00 amRNSFinal Results
12th Aug 20223:30 pmRNSDirector Dealing
28th Jul 20227:00 amRNSCompletion of Convertible Loan Note Fundraising
11th Jul 20227:00 amRNSTrading Update and Notice of Results
22nd Apr 20229:14 amRNSHolding(s) in Company
2nd Mar 20227:00 amRNSTrading Update
12th Jan 20227:00 amRNSSenior Management Appointment
14th Dec 20219:06 amRNSSecond Price Monitoring Extn
14th Dec 20219:00 amRNSPrice Monitoring Extension
13th Dec 20217:00 amRNSDirectorate Change
9th Dec 20218:51 amRNSDirector Dealing
8th Dec 20217:00 amRNSInterim Results and Investor Presentation
2nd Nov 20217:00 amRNSDirectorate and Senior Management Changes

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.